Search
taselisib
Indications:
- treatment of PI3K mutation positive breast cancer in combination with hormonal therapy fulvestrant (Faslodex)
Adverse effects:
- substantial toxicity may preclude use
Mechanism of action:
- inhibits PI3K
General
enzyme inhibitor
small inhibitory antineoplastic agent (ib drug)
Database Correlations
PUBCHEM cid=51001932
References
- Smith M.
PI3K Inhibitor Has Mixed Results in Advanced Breast Cancer
Modest progression benefit, but substantial side effects, with
taselisib.
MedPage Today. June 03, 2018
https://www.medpagetoday.com/meetingcoverage/asco/73239
- Baselga J, et al
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v
FULV in patients (pts) with estrogen receptor (ER)-positive,
PIK3CA-mutant (MUT), locally advanced or metastatic breast
cancer (MBC): Primary analysis from SANDPIPER.
American Society of Clinical Oncology (ASCO) 2018;
Abstract LBA1006.